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Abstract
Objective: To develop a primary aldosteronism (PA) disease-specific Health-Related 
Quality of Life (HRQoL) questionnaire.
Methods: We included newly diagnosed patients with PA (n = 26), and patients with PA 
after adrenalectomy (n = 25) or treated with mineralocorticoid receptor antagonists 
(n = 25). According to the guidelines for developing HRQoL questionnaires from the 
European Organization for Research and Treatment of Cancer (EORTC): Phase I: 
systematic literature review followed by focus group meetings with patients (n = 13) 
resulting in a list of 94 HRQoL issues. Relevance of issues was rated by 18 other patients 
and by health care professionals (n = 15), resulting in 30 remaining issues. Phase II: 
selected issues were converted into questions. Phase III: the provisional questionnaire 
was pre-tested by a third group of patients (n = 45) who also completed the EORTC core 
Quality of Life questionnaire (QLQ-C30). Psychometric testing resulted in a final selection 
of questions with their scale structure.
Results: After the collection and selection of HRQoL issues a provisional questionnaire 
consisting of 30 items was formed. Of these items, 26 could be assigned to one of the 
four scales ‘physical and mental fatigue’, ‘anxiety and stress’, ‘fluid balance’ and ‘other 
complaints’ cumulatively accounting for 68% of variation in all items. All scales had good 
reliability and validity. There was a significant correlation of all four scales with the  
QLQ-C30 in most cases.
Conclusions: We developed the first PA-specific HRQoL questionnaire (PA-QoL) using 
standard, methodologically proven guidelines. After completion of the final validation 
(phase IV, international field testing), the questionnaire can be implemented into clinical 
practice.
Introduction
Primary aldosteronism (PA) is a common cause 
of hypertension, accounting for 5–15% of 
hypertensive patients (1, 2, 3). PA is categorized 
in an aldosterone-producing adenoma (APA) or 
bilateral adrenal hyperplasia (BAH). When unilateral 
aldosterone hypersecretion is suspected (APA), 
patients generally undergo adrenalectomy (ADX). 
Patients with BAH receive a mineralocorticoid receptor 
antagonist (MRA).
Over the last decade, there has been increasing 
interest in the patient perspective with the assessment of 
HRQoL, commonly defined by the functional effect of an 
illness and/or its treatment upon a patient, as perceived 
by the patient (4).
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HRQoL studies in patients with PA demonstrated 
a reduced HRQoL compared to reference values (5, 6) 
and improvement in HRQoL after ADX (5) and during 
MRA-based treatment (6). Furthermore, psychological 
symptoms impairing HRQoL in patients with PA have 
been reported: occurrence of anxiety disorders and 
stress is higher than in the general population (7) and in 
patients with essential hypertension (8). Also, depression, 
somatization, psychological distress and a lower level 
of well-being among patients with PA compared to 
healthy controls have been demonstrated (8). This can be 
explained by overstimulation of the abundantly present 
mineralocorticoid receptors in brain structures that are 
involved in fear and anxiety (9), as well as the multiple 
drugs needed to control blood pressure and hypokalemia 
(and thereby adverse reactions) to which patients 
affected by PA are frequently exposed to. Additionally, 
uncontrolled hypertension, especially when it cannot 
be explained by their physician and diagnostic delay can 
increase anxiety and stress.
For the assessment of HRQoL, it is usually 
recommended that a generic HRQoL questionnaire 
(assessing multiple domains of HRQoL) is combined 
with a disease-specific questionnaire (assessing HRQoL 
aspects relevant for a specific disease) (10). In previously 
conducted studies among patients with PA, HRQoL was 
assessed with a generic HRQoL questionnaire (for example 
the Short Form 36 General Health Survey (SF-36)). No 
disease-specific HRQoL questionnaire for patients with PA 
is currently available. Therefore, the aim of this study was 
to develop a PA-specific HRQoL questionnaire in order to 
be able to assess HRQoL and the effect of treatment in PA 
more accurately.
Methods
Patients and study design
The European Organization for Research and Treatment 
of Cancer (EORTC) is an independent, non-profit cancer 
research organization which coordinates and conducts 
international translational and clinical research to 
improve the standard of cancer treatment for patients. 
The EORTC Quality of Life Group is dedicated to the 
development of HRQoL questionnaires. We decided to 
develop our questionnaire according to their guidelines 
for developing HRQoL questionnaires as this is the most 
widely used and comprehensive guideline in the field (11, 
12, 13). The questionnaire will not be part of the EORTC 
portfolio, since the latter is primarily designed for use 
in cancer clinical trials, but the guideline can be used in 
other research settings and clinical practice as well (11).
Below we describe the different phases of development 
of a PA-specific HRQoL questionnaire. All patients included 
in this study were treated at the Radboud University 
Medical Center, had been diagnosed with PA (aldosterone 
after intravenous salt loading test >280 pmol/L or 
140–280 pmol/L and positive consensus of PA by an 
expert panel) (14) and had sufficient Dutch language skills 
(15). All patients have undergone subtyping by adrenal 
vein sampling (cut-off value for selectivity index ≥3 and 
for lateralization index ≥4). The Ethics Committee of 
the Radboud University Medical Center judged that no 
detailed review was warranted given the non-intrusive and 
non-experimental character of this study. We obtained 
written informed consent of all patients.
Phase I
This phase was aimed at compiling an exhaustive list 
of HRQoL issues relevant to patients with PA. For this 
purpose, three sources were used. First, we performed 
an extensive systematic literature search identifying all 
studies investigating HRQoL, related constructs as well 
as physical and mental symptoms in patients with PA, 
published previously (16). The review resulted in a list 
of issues. Second, we organized two patient focus group 
meetings. We invited 43 patients, of whom 13 were 
willing to participate: one meeting for untreated patients 
(no previous ADX and no use of MRA; n = 5) and one for 
patients treated by ADX (n = 4) or with MRA (n = 4). Treated 
patients were included in order to explore treatment-
related HRQoL issues. Furthermore, these patients could 
also contribute to the issues they experienced before 
treatment, by remembering the changes caused by 
the treatment and comparing pre- and post-treatment 
period. In these qualitative interviews, we collected all 
possible relevant issues for HRQoL in a semi-structured 
way. Additionally we asked the patients to describe their 
experience and to provide information freely. Finally, 
they were asked to add missing issues on a form, in view 
of privacy matters. We recorded these meetings and wrote 
out these recordings verbatim. From these, two authors 
(MV and AN) made a list of issues and combined this with 
the items from the list from the literature review.
We presented this combined list to health care 
professionals (HCP n = 15) with expertise in the field of PA 
from different countries and with different professional 
background and to another group of 18 patients (untreated 
n = 6; ADX n = 6; MRA n = 6, invited n = 39). These were all 
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asked to indicate the relevance on a four-point Likert scale 
(1 = not at all; 2 = a little bit; 3 = moderately; 4 = extremely) 
and to select a maximum of 15 most important issues. 
An issue was selected for inclusion in Phase II on the 
condition that the mean score for both patients and HCPs 
was >2 and/or that >30% of the patients stated an issue as 
important. We also asked them to indicate missing issues, 
serving as our third source for HRQoL issues.
Phase II
We converted the final list of HRQoL issues into Dutch 
questions (items) fitting the following response options 
‘not at all’, ‘a little’, ‘quite a bit’ and ‘very much’. When 
available, we used phrases that had been used previously 
in EORTC HRQoL modules (17).
The Dutch questions were then translated into 
English by applying an iterative forward–backward 
procedure (18).
Phase III
We asked 45 patients not included in phase I (untreated 
n = 15; ADX n = 15; MRA n = 15, invited n = 54) to fill out the 
provisional questionnaire together with the EORTC core 
cancer quality of life questionnaire (QLQ-C30) online in 
Castor EDC (Ciwit B.V. 2017) or, when preferred, on paper. 
The QLQ-C30 served as a generic HRQoL questionnaire 
for validation purposes and is a standard item in this 
phase according to the EORTC guideline (11). When 
specific HRQoL items are included in the provisional 
questionnaire, there should be an adequate correlation 
with the QLQ-C30. Most questions (1–26) referred 
to the patient’s experience during the last week, some 
(27–30) to the patient’s experience during the last 4 weeks. 
Additionally they underwent a debriefing in which they 
had to indicate whether they felt any questions to be 
confusing, intrusive, annoying or upsetting. Furthermore, 
we asked patients to indicate any missing questions. For 
every item we checked the following criteria for inclusion 
in the final questionnaire (response categories: 1 = not 
at all; 2 = a little; 3 = quite a bit; 4 = very much): 1. Mean 
score >1.5; 2. Prevalence ratio >30% (number of patients 
reporting score 2, 3 or 4); 3. Range >2 points; 4. Responses 
of scores in categories 1/2 and 3/4 >10%; 5. No significant 
concerns expressed by patients; 6. Response >95%. When 
>2 criteria were not met in the total group (n = 45) nor in 
the untreated group (n = 15), we did not include the item 
in the final questionnaire. Items with low correlation with 
the total of other items were excluded for the final factor 
analysis (initial communalities <0.1, see data analysis). For 
the issues added in the last step of phase I (missing issues), 
patients had to indicate the relevance and importance 
according to phase I and issues were included in the final 
questionnaire on corresponding condition (mean score >2 
and/or >30% of the patients stated an issue as important).
For a disease-specific HRQoL questionnaire, it is not 
possible to include healthy or essential hypertension 
controls for any comparison in this phase, because not all 
questions are applicable for them.
Data analysis
We performed all analyses in SPSS version 22.0 for 
Windows (SPSS Inc.). We used descriptive statistics for 
phase I and phase III.
We tested the suitability of the data for exploratory 
factor analysis with the Kaiser–Meyer–Olkin (KMO) 
method, of which the value must be >0.5 (19). Initial 
communalities, estimates of the variance in each variable 
accounted for by all factors, were determined (R2 between 
one variable and all others in multiple regression 
analysis). We used exploratory factor analysis to explore 
the underlying constructs, explaining significant portions 
of variance. We based the number of constructs on the 
Kaiser–Guttman rule (the amount of the total variance 
explained by that factor must be >1) and the Cattell’s 
scree plot. We analyzed the factor loadings to explain 
the meaning of each construct. This was done by oblique 
rotation, which assumes that the factors could be related, 
simplifying their interpretation. Only items with factor 
loadings of >0.325 were retained for further analysis.
We performed multi-trait scaling analysis to confirm 
the scale structure found in exploratory factor analysis. 
We examined for item-scale convergent validity, corrected 
for overlap. We tested item-scale discriminant validity by 
comparing the correlation of each item with its own scale 
versus the other scales. Convergent and discriminant 
validity are subtypes of construct validity. Demonstration 
of both convergent and discriminant validity implicates 
construct validity, that is the questions are actually 
measuring what they are supposed to measure.
We tested reliability by measuring Cronbach’s 
alpha coefficient, of which the preferred level is >0.7 
(20). Additionally convergent and discriminant validity 
were examined by calculating Spearman’s correlations 
between the scales and the items and between the 
scales/items and those of the EORTC QLQ-C30 (21). 
For the inclusive criterion, we considered an item-scale 
correlation of >0.40 (corrected for overlap) as adequate. 
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The exclusive criterion was met on the condition that 
the correlation with the other scales was lower than the 
correlation with the corresponding scale. When both 
criteria were met, we concluded that there was scaling 
fulfillment (20).
For the summed (scale) scores, all answers of the items 
contributing to the scale were summed, with a higher score 
corresponding with a lower HRQoL. Finally, we compared 
all summed scale scores and the total score (also added 
up) of the three patient groups with the Kruskal–Wallis 
H test.
Results
Phase I
The patient characteristics are listed in Supplementary 
Table 1 (see section on supplementary data given at the end 
of this article). We included 15 studies in our systematic 
review (16), from which we extracted 66 HRQoL issues. 
Both focus group meetings resulted in an additional 28 
issues. These 94 issues were rated by 18 patients (mean 
age 53  years) and 15 HCP (ten Dutch and five other 
European professionals; six internist-vascular specialists, 
six endocrinologists, two nurses and one surgeon). This 
resulted in the removal of 65 issues. As more than one 
patient indicated ‘edema’ as missing issue, we added this 
to the list.
Phase II
The resulting 30 issues were converted into questions, 
resulting in the provisional PA-QoL. Whenever possible, 
we selected questions from the EORTC item bank 
(http://www.eortc.be/itemlibrary/), a collection of all 
available EORTC (HRQoL) questionnaires. The issues for 
which no corresponding question was available in the 
EORTC item bank (n = 11) were converted into questions 
after consensus by MV, JD and OH, in line with the 
EORTC style.
Phase III
All questionnaires were filled out completely. This 
was done online by 37 patients and on paper by eight 
patients. Patient characteristics are shown in Table  1. 
Response information is provided in Table 2. The time for 
completion of the provisional PA-QoL was ≤10 min for 
24 patients, 11 to 15 min for 15 patients, 16 to 20 min 
for three patients and 21 to 25 min for three patients. 
Two patients indicated gynecomastia as a missing item. 
Therefore, this item was added as a single item only for 
men on spironolactone.
We excluded item 24 about impaired concentration 
based on our pre-defined criteria (mean score was <1.5 
for the total group as well as for the untreated patients, 
prevalence ratio <30% and responses of scores ‘quite a 
bit’/‘very much’ <10%). We treated the item regarding 
erectile dysfunction as a single item. The KMO value for 
the remaining 28 items was 0.78. All initial communalities 
were >0.1. Four factors were identified, cumulatively 
accounting for 68% of variation in all items (respectively 
48, 9, 6 and 5%). The oblique rotation of the exploratory 
factor analysis resulted in factor loadings and correlations 
which are shown in Table 3. We adopted a cut-off value 
of 0.325 for factor loadings. In other words, only those 
Table 1 Characteristics of the patient groups involved in phase III.
Characteristics Untreated (n = 15) MRA-based treatmenta (n = 15) Adrenalectomy (n = 15)
Gender M/F 9/6 13/2 12/3)
Age (years)b 50.7 ± 10.4 59.6 ± 10.3 55.7 ± 8.3
Subtype APA/BAH 9/5c 0/15 15/0
Years since diagnosis of PA (SLT)b <1 4.6 ± 1.4 3.8 ± 0.8
Years since diagnosis of hypertensionb 11.3 ± 8.7 17.2 ± 12.3 15.6 ± 12.1
Years since (start of) treatmentb NA 3.9 ± 1.8 2.7 ± 0.4
Hypokalemia yes/nod 11/4 2/13 0/15
Systolic BP at first visitb 159 ± 23 162 ± 22 155 ± 18
Diastolic BP at first visitb 94 ± 12 92 ± 9.8 92 ± 14
Number of antihypertensive drugs at first visite 2 (1–3) 2 (1–4) 2 (1–3)
Renin concentration (SLT at T = 0) (mU/L)e,f,g 4.9 (2.0–8.5) 3.4 (3.0–4.6) 5.1 (3.0–9.2)
Aldosterone concentration (SLT at T = 4 h) (nmol/L)e,f,h 0.48 (0.33–0.77) 0.38 (0.31–0.47) 0.49i (0.32–1.09)
aSpironolacton (n = 6), eplerenon (n = 8), methyldopa (n = 1, due to pregnancy wish); bmean ± SD; cunknown in one patient; dat time of filling out 
questionnaire; emedian (25th–75th percentile); fpre-treatment; gn = 11/13/10 (missings due to renin activity measurements in other patients), if renin was 
<3 (n = 11) it was considered as renin = 3, reference values 6.2–65 mU/L; h>0.28 nmol/L confirms PA; in = 14.
APA, aldosterone-producing adenoma; BAH, bilateral adrenal hyperplasia; NA, not applicable; PA, primary aldosteronism; SLT, salt loading test.
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items scoring higher than this threshold were retained for 
further analysis. As a result, we treated item 13 (snoring) 
and item 21 (impatient) also as single items.
The multi-trait analysis showed that scaling 
assumptions were not met for one item in three of the four 
scales (Table 4). The reliability of all scales was adequate. 
There was a significant correlation of all four scales with 
the EORTC QLQ-C30 in most cases (Table 5). We named 
the scales physical and mental fatigue, anxiety and stress, 
fluid balance and other complaints.
The summed scale scores were the highest for the 
untreated patients and the lowest for the patients after ADX 
(Table 6). This was statistically significant for scale 2 and 
for the total of all 28 items (item concerning erectile 
dysfunction not included).
Discussion
We have developed the first disease-specific HRQoL 
questionnaire for patients with PA, the PA-QoL, consisting 
of the 30 most relevant items, according to an established 
guideline (11). This preliminary analysis resulted in 
four scales, all with a fair reliability and validity. There 
is an adequate correlation with the validated EORTC 
Table 2 Item descriptive statistics of 45 patients with (treated) primary aldosteronism (phase III).
 
Item
 
Question
Mean
Distribution of responses 
(n = 45)a
Total  
(n = 45)
Untreated  
(n = 15)
MRA  
(n = 15)
ADX  
(n = 15) 1 2 3 4
1 Have you had headaches? 1.38 1.53 1.40 1.20 30 13 2 0
2 Have you had muscle weakness? 1.38 1.40 1.60 1.23 33 8 3 1
3 Have you been physically limited? 1.73 2.00 1.87 1.33 24 13 4 4
4 Have you lacked energy? 1.89 2.20 1.93 1.53 17 19 6 3
5 Have you felt restless or agitated? 1.47 1.80 1.40 1.20 30 10 4 1
6 Have you felt physically exhausted? 1.56 1.93 1.53 1.20 27 14 1 3
7 Have you felt mentally exhausted? 1.47 1.67 1.40 1.33 31 10 1 3
8 Have you had to urinate frequently during the day? 1.69 1.87 1.60 1.60 22 15 8 0
9 Have you had to urinate frequently at night? 2.04 2.07 2.27 1.80 11 23 9 2
10 Have you felt overly thirsty? 1.58 1.93 1.47 1.33 28 8 9 0
11 Have you taken large quantities of fluid? 1.56 1.87 1.33 1.47 28 9 8 0
12 Have you woken up for long periods during the night? 1.71 1.53 1.93 1.67 23 14 6 2
13 Have you, as far as you know, snored? 2.09 2.33 1.87 2.07 15 16 9 5
14 Did you feel sleepy during the day? 1.84 2.20 1.67 1.67 16 22 6 2
15 Have you felt tired (not rested) when you woke up? 1.84 2.20 1.80 1.53 20 14 9 2
16 Have you worried about the consequences of your 
high blood pressure? 
1.64 2.07 1.57 1.40 24 15 4 2
17 Have you been worried about the consequences of 
the elevated levels of aldosterone?
1.76 2.27 1.67 1.33 21 16 6 2
18 Have you worried about your treatment causing 
future health problems?
1.71 1.87 1.93 1.33 22 15 7 1
19 Have you been worried about the side effects of 
your treatment?
1.71 2.00 1.80 1.33 23 14 6 2
20 Have you felt frustrated about the number of pills 
that you are taking?
1.93 2.20 1.87 1.73 22 10 7 6
21 Have you felt impatient? 1.49 1.67 1.60 1.20 29 11 4 1
22 Did you feel irritable? 1.69 2.00 1.67 1.40 22 16 6 1
23 Did you get angry easily? 1.58 1.73 1.60 1.40 25 15 4 1
24b Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 
1.36 1.40 1.33 1.33 32 11 1 1
25 Have you had difficulty remembering things? 1.58 1.60 1.60 1.53 23 19 2 1
26 Have you had swelling in your legs or ankles? 1.47 1.80 1.40 1.20 31 9 3 2
27 Have you felt frustrated about a possible delay in 
the diagnosis of primary aldosteronism?
1.49 2.00 1.33 1.13 31 6 8 0
28 Have you felt worried about the diagnosis? 1.53 2.07 1.33 1.20 28 11 5 1
29 Have you had decreased libido? 1.82 1.93 1.80 1.73 25 8 7 5
30 For men: Did you have difficulty obtaining or 
maintaining an erection? 
1.68
n = 34
1.78
n = 9
2.08
n = 13
1.17
n = 12
22 4 5 3 
Patients were untreated, after adrenalectomy (ADX) or on mineralocorticoid receptor antagonists (MRA).
a1 = not at all; 2 = a little; 3 = quite a bit; 4 = very much; bitem deleted based on pre-defined criteria (see text).
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QLQ-C30 questionnaire. Also, the PA-QoL demonstrates 
the differences in HRQoL between the different treatment 
groups, with the lowest QoL in untreated patients and 
the highest in patients treated by ADX, as established 
before (22).
This is the first study which assessed all specific and 
relevant QoL issues in patients with PA, with contributions 
of 76 patients with PA. The items included in the provisional 
questionnaire cover a range of difficulties that patients 
with PA are facing. Some of them can be directly assigned 
to the pathophysiological effects of high aldosterone, such 
as edema, disturbances of the fluid balance and muscle 
weakness (mediated by hypokalemia). The questionnaire 
also consists of a number of mental issues, which is in line 
with earlier findings (16). Sleeping disorders and snoring 
might be due to the association of PA with obstructive 
sleep apnea (23). Finally, a decreased libido and erectile 
dysfunction might be the result of spironolactone, as this 
mineralocorticoid receptor antagonist has anti-androgen 
activity (24). All these issues are specific for PA and are not 
covered by a general HRQoL questionnaire. Remarkably 
the specific issues concerning depression and generalized 
anxiety were not included in phase III because relevance 
and importance was judged low by patients and HCPs, 
although these problems are known from the literature as 
associated with PA (16).
Table 3 Rotated component matrix of all items with a factor loading >0.325.
Scale Item Description Factor loadings Correlations
Physical and mental fatigue 2 Muscle weakness −0.391 −0.645
3 Physically limited −0.663 −0.806
4 Lack energy −0.531 −0.783
6 Physically exhausted −0.331 −0.706
7 Mentally exhausted −0.777 −0.882
12 Woken up long period night −0.633 −0.668
14 Sleepy daytime −0.582 −0.766
15 Tired wake up −0.326 −0.641
25 Problems remember −0.682 −0.663
29 Decreased libido −0.454 −0.602
Anxiety and stress 5 Restless agitated −0.463 0.623
16 Worries high blood pressure −0.663 −0.714
17 Worries aldosterone −0.988 −0.947
18 Worries future health −0.704 −0.820
19 Worries side effects −0.864 −0.893
20 Frustrated number pills −0.432 −0.551
27 Frustrated delay diagnosis −0.645 −0.733
28 Worries diagnosis −0.842 −0.818
Fluid balance 9 Urinate night 0.426 0.566
10 Thirsty 0.737 0.802
11 Fluids 0.779 0.789
Other complaints 1 Headaches 0.654 0.724
8 Urinate frequently day 0.663 0.674
22 Irritable 0.757 0.893
23 Angry 0.668 0.779
26 Swelling legs ankles 0.448 0.510
Table 4 Results of multi-trait analysis.
Scale N
 
Mean (s.d.) Cronbach’s α
Item-scale convergent validity 
(inclusive criterion)
Item-scale divergent validity  
(exclusive criterion)
Scaling 
fulfillment
Range (mean) of 
item-scale 
correlationsa
Number of 
item-scale 
correlationsb
Range (mean) of 
correlations with 
other scalesc
Number of items 
higher correlations 
with other scaled
Number of items 
that meet 
criterion 1 and 2
1 10 16.8 (6.7) 0.93 0.39–0.79 (0.64) 9/10 0.23–0.76 (0.44) 0/10 9/10
2 8 13.2 (5.5) 0.92 0.51–0.87 (0.69) 8/8 0.29–0.74 (0.42) 1/8 7/8
3 3 5.2 (2.0) 0.77 0.55–0.67 (0.61) 3/3 0.31–0.52 (0.42) 0/3 3/3
4 5 7.8 (2.9) 0.84 0.37–0.81 (0.62) 4/5 0.25–0.77 (0.48) 0/5 4/5
aCorrelation between items and hypothesized scale; bnumber of item-scale correlation that meet minimum standard for convergent validity (≥0.40); 
ccorrelation between items and other scales; dnumber of items that have higher correlation with at least one of the other scales compared to that with 
the hypothesized scale.
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This study confirms the impaired HRQoL of patients 
with PA, and its improvement by treatment. An impaired 
HRQoL has been reported by various studies before (5, 6, 16, 
22, 25), as well as the improvement after therapy (5, 6, 16, 
22, 26). In our study, patients after ADX have a better disease-
specific HRQoL than patients on MRA-based treatment. This 
is in line with our earlier findings with a generic HRQoL 
questionnaire (22). However, in other studies, this relation 
between therapy for PA and QoL has been questioned 
(6, 25). This inconsistency might have been the result of a 
too small number of patients and/or the use of a general/less 
extensive HRQoL questionnaire. As the PA-QoL is disease-
specific, it has presumably more potential to discriminate.
A few limitations should be taken into account. Firstly, 
the PA-QoL has not yet been tested in a large group of patients 
from different countries. Therefore, the created scales have 
a preliminary status. Furthermore, because the scaling 
is mainly a result of statistical procedures, the grouped 
items are not always consistent with how we would create 
scales intuitively. Therefore, the scale structure needs to be 
confirmed in a large international sample of patients with PA. 
Also, one item regarding gynecomastia (‘Have you had 
sore or enlarged nipples or breasts?’) was added to the 
questionnaire specifically for men using spironolactone 
as a single item. The relevance will be checked in the final 
phase. Moreover, when interpreting the outcome of the 
PA-QoL, we have to take into account the possibility of 
a selection bias, which might have influenced the scores 
(in all groups) in phase III, assuming that patients with 
more complaints are more willing to participate for 
example. However, we do not think this has influenced 
the final questionnaire because a lot of issues were 
eliminated in the following phases due to the elaborated 
process of constructing this questionnaire. Finally, the 
gender distribution in phase III might have influenced 
our results. It has been suggested in previous studies that 
(untreated) female patients are more affected regarding 
mental QoL (25), anxiety and depression (7, 8, 27). In our 
study, more male patients were included, especially in the 
post-treatment groups. This is a result of a structural 
higher percentage of men compared to women with PA 
that are treated in our hospital.
Table 5 Correlations between EORTC QlQ-C30 and scales/items PA-QoL.
 
 
EORTC QLQ-C30
Scales
Single items1 2 3 4
Physical and mental fatigue Anxiety and stress Fluid balance Other complaints Snoring Impatience
Physical functioninga −0.77** −0.37* −0.47** −0.67** −0.18 −0.51**
Role functioninga −0.77** −0.52** −0.45** −0.61** −0.16 −0.43**
Emotional functioninga −0.78** −0.53** −0.48** −0.73** −0.29 −0.65**
Cognitive functioninga −0.73** −0.54** −0.50** −0.74** −0.46** −0.68**
Social functioninga −0.72** −0.63** −0.38** −0.52** −0.33* −0.66**
Global QoL/health status −0.63** −0.58** −0.41** −0.63** −0.33* −0.51**
Fatigue 0.87** 0.45** 0.45** 0.75** 0.21 0.50**
Nausea/vomiting 0.54** 0.30* 0.30* 0.39** 0.20 0.26
Pain 0.60** 0.29 0.13 0.36* 0.06 0.30*
Dyspnea 0.63** 0.26 0.27 0.52** 0.06 0.30*
Sleep/insomnia 0.60** 0.52** 0.33* 0.49** 0.32* 0.42**
Appetite loss 0.51** 0.34* 0.43** 0.52** 0.33* 0.58**
Constipation 0.07 −0.05 0.04 0.15 0.26 −0.06
Diarrhea 0.27 0.18 0.20 0.26 0.06 0.24
Financial difficulties 0.28 0.32* 0.30* 0.27 0.27 0.19
<0.40 weak correlation, 0.40–0.60 moderate and >0.60 high.
aA high score for these functional scales represents a high/healthy level of functioning; *P < 0.05; **P < 0.01.
Table 6 Comparison of treatment groups for outcomes provisional PA HRQoL questionnaire.
Scale Items (n) Untreated (n = 15) MRA-based treatment (n = 15) Adrenalectomy (n = 15) P value
1 Physical and mental fatigue 10 18 (14–22) 14 (12–21) 13 (11–17) 0.134
2 Anxiety and stress 8 9 (8–12) 13 (9–14) 9 (8–12) 0.006
3 Fluid balance 3 6 (4–7) 4 (4–6) 4 (3–5) 0.112
4 Other complaints 5 8 (6–12) 7 (5–10) 6 (5–9) 0.192
Total 28 38 (23–43) 42 (36–49) 49 (40–64) 0.027
Data expressed as medians (25th–75th percentile).
MRA, mineralocorticoid receptor antagonists.
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The PA-QoL could be used in clinical as well as research 
setting to measure an important outcome, especially 
from the patients’ perspective. This will allow a more 
optimal and precise mapping of the impaired HRQoL in 
patients with PA and make physicians more aware of the 
potential HRQoL issues that patients with PA are dealing 
with. Furthermore, it will help them to inform patients 
adequately and to identify those who most suffer from 
PA-related health problems, other than hypertension or 
hypokalemia.
The final phase of the development of the PA-QoL 
will assess responsiveness to change and cross-cultural 
validity. The larger number of patients will help to fully 
validate the scales. We expect that this will also result 
in a significant difference between treatment groups in 
all subscales. In our study for two out of three subscales, 
there was a non-significant trend, probably due to the 
limited number of patients in each group (n = 15).
In conclusion, we developed the first PA-specific 
HRQoL questionnaire using standard, methodologically 
proven guidelines. This questionnaire can be of value in 
the care for patients with PA. After final validation in phase 
IV is completed, it can be implemented into practice.
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